GLP-1/GIP agonists significantly reduce appetite and food intake, which is their intended mechanism for weight loss
Fatigue is sometimes reported during the first two weeks at this dose, though it is difficult to determine whether this is a direct effect of the medication or a consequence of significantly reduced caloric intake
Newer medications, other injectable weight loss treatments, are priced similarly to semaglutide, costing around $1,200 per month without insurance
For example, berberine, often called natures Ozempic, has been shown to improve insulin sensitivity, reduce blood sugar levels, and potentially promote mild weight loss by activating an enzyme called AMPK, which regulates metabolism and energy use
Civic Science